Aridis Pharmaceuticals to Postpone Investor Day Due to Coronavirus Concerns
SAN JOSE, Calif., March 6, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today the postponement of its Investor Day scheduled for Thursday, March 12th, 2020 to a future date due to concerns related to the coronavirus (COVID-19).
"Given the current health and safety risks associated with the coronavirus and on-going travel concerns we felt it was prudent to make the precautionary decision to postpone the Investor Day," commented Vu Truong, Ph.D., Chief Executive of Aridis Pharmaceuticals. "We look forward to rescheduling the forum which will include showcasing APEX™, our cutting-edge antibody discovery and production platform and Key Opinion Leader panel discussions on cystic fibrosis and pneumonia."
About Aridis Pharmaceuticals, Inc.
The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as VAP and HAP. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients. The company's pipeline is highlighted below:
AR-101 (HAP). AR-101 is a fully human immunoglobulin M, or IgM, mAb targeting P. aeruginosa liposaccharides serotype O11, which accounts for approximately 22% of all P. aeruginosa hospital acquired pneumonia cases worldwide.
AR-501 (cystic fibrosis). AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in cystic fibrosis patients. This program is currently in a Phase 1/2a clinical study in healthy volunteers and CF patients.
AR-401 (blood stream infections). AR-401 is a fully human mAb preclinical program aimed at treating infections caused by gram-negative Acinetobacter baumannii.
AR-201 (RSV infection). AR-201 is a fully human IgG1 mAb preclinical program aimed at neutralizing diverse clinical isolates of respiratory syncytial virus (RSV).
For additional information on Aridis Pharmaceuticals, please visit https://aridispharma.com/.
View original content to download multimedia:http://www.prnewswire.com/news-releases/aridis-pharmaceuticals-to-postpone-investor-day-due-to-coronavirus-concerns-301019161.html
SOURCE Aridis Pharmaceuticals, Inc.
Company Codes: NASDAQ-NMS:ARDS